Bristol-Myers Squibb Co. (BMY: Quote) and Pfizer Inc. (PFE: Quote) said the Phase III Aristotle trial of Eliquis in comparison with warfarin for the the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation were consistent with the overall results of the Aristotle trial. Further, the companies said the Eliquis compared with warfarin reduced stroke or systemic embolism, caused fewer major bleeding events, and reduced all-cause mortality in NVAF patients with or without valvular heart disease or VHD.
The Aristotle trial excluded patients with clinically significant mitral stenosis, or a mechanical prosthetic heart valve.
The results of the sub analysis were presented in an oral session today at the ESC Congress 2013 in Amsterdam, The Netherlands.
The subanalysis evaluated Eliquis compared to warfarin in patients with or without other types of VHD, who were eligible for enrollment in the Aristotle
trial, including mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis, tricuspid regurgitation, or valve surgery. 4,808 patients
participated in the sub analysis.
Eliquis is an oral inhibitor of blood clotting protein Factor Xa.
Click here to receive FREE breaking news email alerts for Bristol-Myers Squibb Co. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com